Which enzyme is most commonly deficient in patients with Alzheimer's disease?
How does the Lineweaver-Burk plot change with a non-competitive inhibitor?
In the context of enzyme inhibition, which approach is generally considered more effective for targeting highly conserved metabolic enzymes?
Which enzyme is responsible for converting pyruvate to acetyl-CoA, thereby linking glycolysis and the TCA cycle?
What role does the enzyme catalase play in cellular metabolism?
Which of the following enzymes is critical for relieving DNA supercoiling during replication and transcription?
A 45-year-old man presents with muscle weakness and cramps. Blood tests reveal hypokalemia. Which enzyme deficiency could result in this condition?
Which of the following enzymes directly catalyzes the decomposition of hydrogen peroxide to water and oxygen without requiring an additional reducing substrate?
Which of the following is a serine protease?
Which of the following is the UNIQUE characteristic feature of glutamate dehydrogenase that distinguishes it from other dehydrogenases?
Explanation: ***Choline acetyltransferase*** - **Choline acetyltransferase (ChAT)** is the enzyme responsible for synthesizing **acetylcholine**, a neurotransmitter crucial for memory and learning. - In Alzheimer's disease, there is a characteristic **degeneration of cholinergic neurons** and a significant reduction in ChAT activity, leading to **acetylcholine deficiency**. *Acetylcholinesterase* - **Acetylcholinesterase (AChE)** is the enzyme that breaks down acetylcholine in the synaptic cleft. - While it's involved in cholinergic signaling, its deficiency is not the primary pathology in Alzheimer's; rather, **inhibitors of AChE** are used therapeutically to increase acetylcholine levels. *Monoamine oxidase* - **Monoamine oxidase (MAO)** is involved in the metabolism of monoamine neurotransmitters like dopamine, norepinephrine, and serotonin. - Its dysfunction is more commonly associated with conditions like **Parkinson's disease** and depression, not the primary deficit in Alzheimer's. *Dopamine β-hydroxylase* - **Dopamine β-hydroxylase (DBH)** catalyzes the conversion of dopamine to norepinephrine. - Dysregulation of norepinephrine pathways can occur in Alzheimer's, but a primary deficiency of DBH is **not a hallmark** of the disease.
Explanation: ***Increased y-intercept, same x-intercept*** - A **non-competitive inhibitor** binds to an allosteric site on the enzyme, reducing its catalytic efficiency (Vmax). - On a Lineweaver-Burk plot, a decrease in **Vmax** results in an **increased y-intercept (1/Vmax)**, while the **x-intercept (-1/Km)** remains unchanged because the inhibitor does not affect substrate binding affinity. *Increased x-intercept, same y-intercept* - This pattern is characteristic of a **competitive inhibitor**, which increases the apparent **Km** (shifting the x-intercept toward zero). - The **Vmax** remains unchanged, so the y-intercept does not change. *Both intercepts increase* - This does not accurately describe any standard inhibition pattern. - In **uncompetitive inhibition**, both Vmax and Km decrease proportionally, creating parallel lines (both intercepts increase, but the slope remains constant). - In **mixed inhibition**, both Km and Vmax are affected, but the pattern varies depending on whether the inhibitor binds preferentially to the enzyme or enzyme-substrate complex. *No change* - No change would indicate that the substance is **not an inhibitor** or has no effect on enzyme kinetics. - Inhibitors, by definition, alter the enzyme's activity and therefore impact the Lineweaver-Burk plot.
Explanation: ***Targeting allosteric sites for better specificity*** - **Allosteric sites** are distinct from the active site and are generally less conserved between different species or even isoforms of the same enzyme, providing better opportunities for **selective inhibition** of specific enzymes over others. - Modulators binding to allosteric sites induce **conformational changes** that can either activate or inhibit enzyme activity, allowing for a more nuanced and **tunable control** over metabolic pathways. *Targeting active sites directly* - Inhibiting the **active site** of highly conserved metabolic enzymes can lead to significant **off-target effects** due to the structural similarity of active sites across various enzymes. - This lack of **specificity** can result in toxicity and undesirable side effects, making it less ideal for differentiating between host and pathogen enzymes or between different metabolic contexts. *Both methods are equally effective in all cases* - The effectiveness of targeting approaches is highly **context-dependent**, influenced by factors such as the specific enzyme, the desired therapeutic outcome, and the potential for off-target effects. - Generalizing that both methods are equally effective overlooks the inherent differences in **selectivity and mechanism of action** offered by active versus allosteric site targeting. *Effectiveness depends on the specific enzyme and context* - While it's true that effectiveness depends on specific enzyme and context, the question asks which approach is *generally* more effective for *highly conserved* metabolic enzymes. - For such enzymes, the **inherent specificity advantage** of allosteric targeting makes it a generally preferred approach over active site targeting.
Explanation: ***Pyruvate dehydrogenase*** - The **pyruvate dehydrogenase complex** catalyzes the oxidative decarboxylation of **pyruvate** to **acetyl-CoA**, releasing carbon dioxide. - This crucial reaction is the committed step that links glycolysis (which produces pyruvate) to the **TCA cycle** (which consumes acetyl-CoA). *Pyruvate carboxylase* - This enzyme converts **pyruvate** to **oxaloacetate**, an important anaplerotic reaction that replenishes intermediates of the **TCA cycle**. - It does not produce acetyl-CoA and is typically involved in **gluconeogenesis**. *Pyruvate kinase* - **Pyruvate kinase** is the final enzyme in **glycolysis**, catalyzing the transfer of a phosphate group from **phosphoenolpyruvate (PEP)** to ADP, generating ATP and pyruvate. - It is an ATP-generating step within glycolysis and does not convert pyruvate to acetyl-CoA. *Lactate dehydrogenase* - This enzyme catalyzes the reversible conversion of **pyruvate** to **lactate**, primarily under anaerobic conditions. - It regenerates NAD+ for glycolysis to continue in the absence of oxygen but does not link glycolysis to the TCA cycle.
Explanation: ***It converts hydrogen peroxide into water and oxygen*** - **Catalase** is an enzyme that specifically catalyzes the decomposition of **hydrogen peroxide (H2O2)**, a harmful reactive oxygen species generated during various metabolic processes. - This conversion into **water (H2O)** and **oxygen (O2)** is crucial for protecting cells from **oxidative damage**. *It synthesizes fatty acids from acetyl-CoA* - The synthesis of fatty acids from **acetyl-CoA** is primarily carried out by **fatty acid synthase**, a multi-enzyme complex, not catalase. - This process is part of **anabolic metabolism**, while catalase is involved in detoxification. *It catalyzes the transfer of phosphate groups in ATP production* - The transfer of phosphate groups for **ATP production** (e.g., during oxidative phosphorylation or glycolysis) is catalyzed by enzymes like **ATP synthase** or **kinases**, respectively. - These enzymes are distinct from catalase, which has a specific role in peroxide breakdown. *It breaks down excess amino acids* - The breakdown of excess amino acids, including their deamination and conversion into other metabolic intermediates, is managed by a variety of enzymes such as **transaminases** and **dehydrogenases**. - Catalase is not involved in amino acid catabolism.
Explanation: ***Topoisomerase*** - **Topoisomerases** are enzymes essential for **relieving torsional stress** by cutting and rejoining DNA strands ahead of the replication fork or transcription machinery - This activity **prevents DNA from becoming excessively supercoiled**, which would otherwise impede replication and transcription processes - Type I topoisomerases create single-strand breaks; Type II create double-strand breaks to manage DNA topology *Helicase* - **Helicase** unwinds the DNA double helix by breaking hydrogen bonds between base pairs, creating the replication fork - While helicase action **creates supercoiling downstream**, it does not relieve this torsional stress - Topoisomerases work ahead of helicase to prevent accumulation of positive supercoils *Ligase* - **DNA ligase** catalyzes phosphodiester bond formation to join DNA fragments, particularly Okazaki fragments on the lagging strand - Functions in DNA repair and replication completion - **No role in managing DNA topology or supercoiling** *Polymerase* - **DNA polymerase** synthesizes new DNA strands during replication; **RNA polymerase** synthesizes RNA during transcription - Both enzymes require topoisomerases to function efficiently by relieving supercoiling - **Do not directly address DNA supercoiling** themselves
Explanation: ***Pyruvate kinase*** - **Pyruvate kinase deficiency** causes **chronic hemolytic anemia** with compensatory increased erythropoiesis and high metabolic demand. - In the context of chronic hemolysis, patients may develop **secondary hypokalemia** due to: increased renal potassium losses from chronic illness, poor nutrition, or associated gastrointestinal losses. - The **muscle weakness and cramps** result from both the chronic anemia (tissue hypoxia, reduced ATP) and the electrolyte disturbance (hypokalemia affects muscle membrane potential). - Among the glycolytic enzyme deficiencies listed, pyruvate kinase deficiency is most commonly associated with chronic systemic complications. *Phosphofructokinase* - **Phosphofructokinase deficiency** (Tarui's disease, glycogenosis type VII) causes **exercise-induced muscle symptoms** including myalgia, cramps, and fatigue. - Results from impaired glycolysis in muscle with glycogen accumulation. - Does not typically cause hypokalemia; may show elevated lactate and myoglobinuria after exercise. *Glucose-6-phosphate dehydrogenase* - **G6PD deficiency** causes **episodic hemolytic anemia** triggered by oxidative stress (infections, drugs, fava beans). - Presents with acute hemolytic crises rather than chronic muscle weakness. - Not associated with chronic hypokalemia as a primary feature. *Aldolase* - **Aldolase deficiency** is extremely rare and can cause **hemolytic anemia**. - May present with myopathy in some variants, but hypokalemia is not a characteristic feature. - Clinical presentation varies depending on which aldolase isoenzyme is affected.
Explanation: ***Catalase*** - **Catalase** directly catalyzes the breakdown of **hydrogen peroxide (H2O2)** into **water (H2O)** and **oxygen (O2)** without requiring any additional reducing substrate. - The reaction is: **2 H2O2 → 2 H2O + O2** - This unique mechanism makes catalase extremely efficient at detoxifying high concentrations of H2O2, particularly in peroxisomes and red blood cells. - Catalase has one of the highest turnover rates of all enzymes (millions of molecules per second). *Superoxide dismutase* - **Superoxide dismutase (SOD)** converts the **superoxide radical (O2•−)** into oxygen and **hydrogen peroxide**. - The reaction is: **2 O2•− + 2 H+ → H2O2 + O2** - While it detoxifies superoxide, it produces hydrogen peroxide, which then requires other enzymes like catalase for further detoxification. *Glutathione peroxidase* - **Glutathione peroxidase (GPx)** reduces **hydrogen peroxide** to water using **reduced glutathione (GSH)** as a reducing substrate. - The reaction is: **H2O2 + 2 GSH → 2 H2O + GSSG** - Unlike catalase, GPx requires glutathione as a co-substrate and works in concert with glutathione reductase to regenerate GSH. *Peroxiredoxin* - **Peroxiredoxins** reduce **hydrogen peroxide** to water using **thioredoxin or glutaredoxin** as reducing substrates. - The reaction requires: **H2O2 + thioredoxin(red) → 2 H2O + thioredoxin(ox)** - They are abundant antioxidant enzymes but depend on the thioredoxin/thioredoxin reductase system, unlike catalase which acts independently.
Explanation: ***Chymotrypsin*** - **Chymotrypsin** is a digestive enzyme that belongs to the class of **serine proteases**, meaning it uses a serine residue in its active site to catalyze peptide bond hydrolysis. - It specifically cleaves peptide bonds adjacent to **aromatic amino acids** (e.g., phenylalanine, tryptophan, tyrosine). *Caspases* - **Caspases** are a family of cysteine proteases, meaning they use a **cysteine residue** in their active site for catalysis. - They play crucial roles in **apoptosis** (programmed cell death) and inflammation. *Carboxypeptidase* - **Carboxypeptidases** are exopeptidases that cleave the **C-terminal amino acid** from a polypeptide chain. - While they are proteases, they do not primarily rely on a serine residue in their active site in the same way as serine proteases; some are metalloproteases (e.g., carboxypeptidase A uses zinc). *Pepsin* - **Pepsin** is an aspartic protease, meaning it uses two **aspartic acid residues** in its active site to cleave peptide bonds. - It functions optimally in the **acidic environment of the stomach** and is responsible for initial protein digestion.
Explanation: ***Can use both NAD+ and NADP+ as coenzymes*** - **Glutamate dehydrogenase (GDH)** is unique among dehydrogenases in its ability to utilize both oxidized forms of nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+) as coenzymes for its reversible reaction. - This **dual coenzyme specificity** is the distinguishing characteristic that sets GDH apart from most other dehydrogenases, which typically use only one type of cofactor. - This feature allows GDH to participate in metabolic pathways that require either cofactor, contributing to its critical role in linking **amino acid and carbohydrate metabolism**. *Liver mitochondrial enzyme, catalyzing reversible oxidative deamination* - While this is a true statement about GDH, many other enzymes are also **mitochondrial** and found in **liver**. - Reversible oxidative deamination is a function but not a **unique distinguishing feature** compared to other dehydrogenases. *Catalyzes the conversion of glutamate to alpha-ketoglutarate and ammonia* - This statement describes the **forward reaction** (oxidative deamination), which is accurate. - However, this describes the **function** of the enzyme rather than a unique characteristic that distinguishes it from other dehydrogenases. - Many enzymes catalyze similar deamination reactions. *Activated by ADP and inhibited by GTP* - This statement correctly describes the **allosteric regulation** of GDH. - However, allosteric regulation by energy status indicators (ADP/ATP, GDP/GTP) is common among metabolic enzymes and is not a **unique distinguishing feature** of GDH specifically among dehydrogenases.
Enzyme Classification and Nomenclature
Practice Questions
Enzyme Kinetics and Michaelis-Menten Equation
Practice Questions
Enzyme Inhibition: Competitive and Non-competitive
Practice Questions
Allosteric Regulation
Practice Questions
Coenzymes and Cofactors
Practice Questions
Isoenzymes and Clinical Significance
Practice Questions
Enzyme Regulation: Covalent Modification
Practice Questions
Enzyme Regulation: Zymogen Activation
Practice Questions
Enzyme Induction and Repression
Practice Questions
Ribozymes and Catalytic RNA
Practice Questions
Enzyme Diagnostic Applications
Practice Questions
Enzyme Therapy and Inhibitors as Drugs
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free